Agilon Health (AGL)

• Market cap: $1.27B
• 1 day: 4.39%
• 5 days: 27.16%
• 1 month: 54.50%
• 3 months: -6.36%
• 6 months: -58.07%
• Year to date: 60.94%
• 1 year: -57.44%
• 5 years: -90.03%
• 10 years: -90.03%
• Sector: Healthcare
• Industry: Miscellaneous Health & Allied Services

About: Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

Employees: 1,117

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

28% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 36

20% more call options, than puts

Call options by funds: $12.2M | Put options by funds: $10.2M

3% more funds holding

Funds holding: 203 [Q2] → 210 (+7) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 63

20.26% less ownership

Funds ownership: 124.65% [Q2] → 104.39% (-20.26%) [Q3]

50% less capital invested

Capital invested by funds: $3.35B [Q2] → $1.69B (-$1.67B) [Q3]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 35% downside
• Avg. target: $2.49 19% downside
• High target: $3.15 2% upside

8 analyst ratings

• positive: 1 13%
• neutral: 6 75%
• negative: 1 13%

Bernstein Amir Farahan 0 / 0 met price target	2% upside $3.15	Market Perform Maintained	15 Jan 2025
Citigroup Daniel Grosslight 39% 1-year accuracy 9 / 23 met price target	27% downside $2.25	Neutral Upgraded	10 Jan 2025
Macquarie Tao Qiu 38% 1-year accuracy 6 / 16 met price target	3% downside $3	Neutral Initiated	16 Dec 2024
Bernstein Lance Wilkes 100% 1-year accuracy 2 / 2 met price target	19% downside $2.50	Market Perform Initiated	11 Dec 2024
RBC Capital Sean Dodge 48% 1-year accuracy 21 / 44 met price target	3% downside $3	Outperform Reiterated	19 Nov 2024